METHODS: Data on patients with EGFR-mutated NSCLC, eligible for TKIs, and treated between 2010 to 2019 were collected. The main therapeutic strategies adopted following progression under TKIs and the prognostic factors for survival were analyzed.
RESULTS: The median age of the 177 patients was included in the cohort was 70years. The majority of patients (77.4%) received TKIs as first-line treatment, while 16.4% received chemotherapy. Osimertinib initiation as second-line treatment was a factor for better prognosis (OR=0.5). Finally, change of chemotherapy line was the main therapeutic strategy adopted for 41.3% of the patients having relapsed under TKIs.
CONCLUSIONS: Therapeutic management of EGFR-mutated NSCLC patients was in accordance with regional, national and international recommendations. The characterization of progression under TKI therapy has become systematic, allowing better adaption of therapeutic strategies.
方法:EGFR突变非小细胞肺癌患者的数据,有资格获得TKIs,并在2010年至2019年期间进行了治疗。分析了在TKIs下进展后采取的主要治疗策略和生存的预后因素。
结果:纳入队列的177名患者的中位年龄为70岁。大多数患者(77.4%)接受TKIs作为一线治疗,16.4%接受化疗。奥希替尼开始作为二线治疗是预后更好的因素(OR=0.5)。最后,化疗线的改变是41.3%的TKIs复发患者采用的主要治疗策略.
结论:EGFR突变的非小细胞肺癌患者的治疗管理符合区域性,国家和国际建议。TKI治疗下的进展表征已经变得系统,允许更好地适应治疗策略。